The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
150 mg/day p.o.
Kurume University, School of Medicine
Fukuoka, Japan
RECRUITINGDepartment of Internal Medicine, Osaka City General Hospital
Osaka, Japan
RECRUITINGOhno memorial Hospital
Osaka, Japan
NOT_YET_RECRUITINGRenal function (Creatinine clearance)
Time frame: One year (every 6 months)
Urinary protein
Time frame: One year (every 6 months)
Urinary angiotensinogen
Time frame: One year (every 6 months)
Urinary type 4 collagen
Time frame: One year (every 6 months)
Urinary Transforming growth factor-beta
Time frame: One year (every 6 months)
High-sensitivity C-reactive protein
Time frame: One year (every 6 months)
Plasma Rennin Activity
Time frame: One year (every 12 months)
Aldosterone
Time frame: One year (every 12 months)
Asymmetric dimethylarginine
Time frame: One year (every 12 months)
Advanced glycation end product
Time frame: One year (every 12 months)
(Pro)renin receptor
Time frame: One year (every 12 months)
Oxidative stress
Time frame: One year (every 12 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kinki University, Faculty of Medicine
Osaka, Japan
RECRUITING